Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Handbook of Nutrition, Diet, and Epigenetics [[electronic resource] /] / edited by Vinood Patel, Victor Preedy
| Handbook of Nutrition, Diet, and Epigenetics [[electronic resource] /] / edited by Vinood Patel, Victor Preedy |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (2000 p.) |
| Disciplina | 616.2 |
| Soggetto topico |
Clinical nutrition
Human genetics Health promotion Molecular biology Clinical Nutrition Human Genetics Health Promotion and Disease Prevention Molecular Medicine |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Nervous system -- Development and ageing -- Cancers -- Caloric and dietary restriction -- Detailed processes in epigenetics of diet and nutrition.-Modifications of DNA via methylation -- Modifications of histones -- Modifications of non-coding RNAs -- DNA repair -- Modulating epigenetics with diet and nutrition -- General treatments and strategies -- Vitamins -- Minerals -- Specific foods and nutrients -- Nutritional toxicology -- Practical techniques . |
| Record Nr. | UNINA-9910349365503321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of Tuberculosis / / Stefan H. E. Kaufmann [and three others]
| Handbook of Tuberculosis / / Stefan H. E. Kaufmann [and three others] |
| Autore | Kaufmann Stefan H. E. |
| Pubbl/distr/stampa | [Place of publication not identified] : , : John Wiley & Sons, Inc., , 2008 |
| Descrizione fisica | 1 online resource (339 pages) |
| Disciplina | 616.2 |
| Soggetto topico |
Mycobacterium tuberculosis
Tuberculosis |
| ISBN | 3-527-61161-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | V. 1. Molecular biology and biochemistry / edited by Stefan H.E. Kaufmann and Eric Rubin -- v. 2. Immunology and cell biology / edited by Stefan H.E. Kaufmann and Warwick J. Britton -- v. 3. Clinics, diagnostics, therapy, and epidemiology / edited by Stefan H.E. Kaufmann and Paul van Helden --. |
| Record Nr. | UNINA-9910830930803321 |
Kaufmann Stefan H. E.
|
||
| [Place of publication not identified] : , : John Wiley & Sons, Inc., , 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Health disparities in respiratory medicine [[electronic resource] /] / edited by Lynn B. Gerald, Cristine E. Berry
| Health disparities in respiratory medicine [[electronic resource] /] / edited by Lynn B. Gerald, Cristine E. Berry |
| Edizione | [1st ed. 2016.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Humana, , 2016 |
| Descrizione fisica | 1 online resource (364 p.) |
| Disciplina | 616.2 |
| Collana | Respiratory Medicine |
| Soggetto topico |
Respiratory organs—Diseases
Health promotion Health administration Pneumology/Respiratory System Health Promotion and Disease Prevention Health Administration |
| ISBN | 3-319-23675-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction to Health Disparities in Respiratory Medicine -- Health Disparities in Tobacco Smoking and Smoke Exposure -- Health Disparities Related to Environmental Air Quality -- Health Disparities in Occupational Exposures -- Health Disparities and Pulmonary Function Testing.- Health Disparities as They Relate to Medication Adherence -- Health Disparities in Ards -- Social Disparities in Lung Growth and Respiratory Health -- Health Disparities in Asthma -- Health Disparities in Chronic Obstructive Pulmonary Disease -- Health Disparities and Tuberculosis -- Disparities in Lung Cancer Outcomes -- Health Disparities in Critical Illness -- Health Disparities in Sleep-Related Breathing Disorders -- Health Disparities in End-of-Life Care -- Where Do We Go From Here? Improving Disparities in Respiratory Health. |
| Record Nr. | UNINA-9910254504903321 |
| Cham : , : Springer International Publishing : , : Imprint : Humana, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Hematologic Abnormalities and Acute Lung Syndromes [[electronic resource] /] / edited by Janet S. Lee, Michael P. Donahoe
| Hematologic Abnormalities and Acute Lung Syndromes [[electronic resource] /] / edited by Janet S. Lee, Michael P. Donahoe |
| Edizione | [1st ed. 2017.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Humana, , 2017 |
| Descrizione fisica | 1 online resource (XI, 265 p. 30 illus., 19 illus. in color.) |
| Disciplina | 616.2 |
| Collana | Respiratory Medicine |
| Soggetto topico |
Respiratory organs—Diseases
Hematology Critical care medicine Pneumology/Respiratory System Intensive / Critical Care Medicine |
| ISBN | 3-319-41912-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part I: Overview -- The Lung-Blood Interface -- Leukocyte Kinetics and Migration in the Lungs -- Part II: Acute Pulmonary Manifestations Arising from Primary Hematologic Disorders -- Sickle Cell and Acute Chest Syndrome: Mechanisms and Pathogenesis -- Sickle Cell Disease and Acute Chest Syndrome: Epidemiology, Diagnosis, Management, Outcomes -- Thrombophilias and Acute Pulmonary Thromboembolic Disease -- Bleeding Disorders: Diagnosis and Treatment of Hemorrhagic Complications in the Intensive Care Unit -- Acute Pulmonary Manifestations of Hematologic Malignancies -- Acute Pulmonary Complications of Bone Marrow and Stem Cell Transplantation -- Part III: Transfusion-Related Complications -- Storage Lesion: Evolving Concepts and Controversies -- Transfusion and Acute Respiratory Distress Syndrome: Pathogenesis and Potential Mechanisms -- Transfusion and Acute Respiratory Distress Syndrome: Clinical Epidemiology, Diagnosis, Management, and Outcomes -- Transfusion Associated Circulatory Overload -- Transfusion-Related Immunomodulation (TRIM): From Renal Allograft Survival to Postoperative Mortality in Cardiac Surgery. |
| Record Nr. | UNINA-9910136018803321 |
| Cham : , : Springer International Publishing : , : Imprint : Humana, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
High altitude sickness - solutions from genomics, proteomics and antioxidant interventions / / Narendra Kumar Sharma and Aditya Arya, editors
| High altitude sickness - solutions from genomics, proteomics and antioxidant interventions / / Narendra Kumar Sharma and Aditya Arya, editors |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (222 pages) |
| Disciplina | 616.2 |
| Soggetto topico |
Anoxemia
Mountain sickness Genomics |
| ISBN | 981-19-1008-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- About the Book -- Contents -- About the Editors -- 1: Introduction to High Altitude and Hypoxia -- 1.1 Introduction -- 1.2 High Altitude and Oxygen Availability -- 1.3 Acclimatization at High Altitude -- 1.3.1 Acute Mountain Sickness -- 1.3.2 High Altitude Cerebral Oedema (HACE) -- 1.3.2.1 Intracellular Oedema -- 1.3.2.2 Ionic Oedema -- 1.3.2.3 Vasogenic Oedema -- 1.3.3 High Altitude Pulmonary Oedema (HAPE) -- 1.4 Hypobaric Hypoxia and Brain -- 1.4.1 Brain as a Vulnerable Site of Oxidative Stress -- 1.4.2 Hypobaric Hypoxia and Memory Functions -- 1.5 Other Neurological Effects at High Altitude -- References -- 2: High Altitude Sickness: Environmental Stressor and Altered Physiological Response -- 2.1 Introduction -- 2.1.1 High Altitudes -- 2.1.2 Environment at High Altitudes and Defining ``Hypoxia´´ -- 2.1.2.1 Identifying the Concept of ``Hypoxia´´ -- 2.1.2.2 Types of Hypoxia -- 2.1.2.3 Symptoms of High Altitude Hypoxia -- 2.1.3 Ultraviolet Radiation -- 2.1.4 Cold -- 2.2 Physiological Changes at High Altitude -- 2.2.1 Acclimatization to High Altitude -- 2.2.1.1 Pulmonary Ventilation or Hyperventilation -- 2.2.1.2 Polycythaemia -- 2.2.2 Affinity of Haemoglobin for Oxygen at Sea Level and At High Altitudes -- 2.2.3 High Altitude and Oxidative Stress -- 2.3 Conclusion -- References -- 3: High Altitude Related Diseases: Milder Effects, HACE, HAPE, and Effect on Various Organ Systems -- 3.1 Introduction -- 3.2 Epidemiology of High Altitude Sickness -- 3.3 Mechanisms of High Altitude Sickness -- 3.4 Milder Effects of High Altitude (AMS) -- 3.5 High Altitude Pulmonary Oedema (HAPE) -- 3.6 High Altitude Cerebral Oedema (HACE) -- 3.7 High Altitude Related Cardiac Perturbations -- 3.8 High Altitude Related Perturbations in Muscles -- 3.9 High Altitude Related Perturbations in Kidney -- 3.10 High Altitude Related Perturbations in Liver.
3.11 Conclusion -- References -- 4: High Altitude-Induced Oxidative Stress, Rheumatoid Arthritis, and Proteomic Alteration -- 4.1 Oxidative Stress -- 4.1.1 Oxidants -- 4.1.1.1 Endogenous Source -- 4.1.1.2 Exogenous Source -- 4.1.2 Antioxidants -- 4.2 High Altitude Mediated Oxidative Stress -- 4.2.1 High Altitude and Oxidative Damage -- 4.2.2 RONS Generation at High Altitude -- 4.2.3 Hypoxia and Oxidative Stress -- 4.3 Rheumatoid Arthritis (RA) -- 4.3.1 Oxidative Stress in RA -- 4.3.2 High Altitude and RA -- 4.3.3 Reactive Species Measurement in RA -- 4.4 Oxidative Stress Measurement -- 4.5 High Altitude and Proteomic Alteration -- 4.6 Conclusion -- References -- 5: Oxidative Stress, ROS Generation, and Associated Molecular Alterations in High Altitude Hypoxia -- 5.1 Introduction -- 5.2 Mechanisms of Oxidant Generation -- 5.2.1 Oxidants Generation in Mitochondria -- 5.2.2 Oxidant Generation in Phagocytic and Non-phagocytic Cells -- 5.3 Defence Mechanism Against Oxidative Stress -- 5.3.1 Enzymatic Antioxidants -- 5.3.2 Non-Enzymatic Antioxidants -- 5.4 Organ-Level Oxidative Damage Manifested by Cellular ROS -- 5.4.1 Oxidative Damage in Lungs -- 5.4.2 Oxidative Damage in Brain -- 5.4.3 Oxidative Damage in Heart -- 5.5 Oxidative Perturbations Mediated Changes in Proteome -- 5.6 Conclusion -- References -- 6: High Altitude Induced Thrombosis: Challenges and Recent Advancements in Pathogenesis and Management -- 6.1 Introduction -- 6.2 Genetic Risk Factors for VTE -- 6.2.1 Factor V Leiden -- 6.2.2 Deficiency of Protein C, Protein S and Antithrombin -- 6.2.3 Prothrombin Mutation -- 6.3 Acquired Risk Factors for VTE -- 6.3.1 Surgery/Trauma -- 6.3.2 Advanced Age -- 6.3.3 Cancer -- 6.3.4 Oral Contraceptives and Hormone Replacement Therapy -- 6.3.5 Immobilization -- 6.4 Modern Lifestyle Risk Factors for VTE -- 6.4.1 Virchow´s Triad. 6.5 Hypoxia at High Altitude -- 6.6 High Altitude Thrombo-Embolism (HATE) -- 6.7 Pathogenesis of HATE -- 6.7.1 Ascent to an Elevated Region -- 6.7.2 Long Haul Air Travel -- 6.7.3 Simulated Hypobaric Hypoxia -- 6.8 Evidence from Pre-Clinical Studies -- 6.9 Clinical Management of HATE -- 6.10 Conclusion -- References -- 7: Current Problems in Diagnosis and Treatment of High-Altitude Sickness -- 7.1 Introduction -- 7.2 Acute Mountain Sickness (AMS) -- 7.3 High-Altitude Cerebral Edema -- 7.4 High-Altitude Pulmonary Oedema (HAPE) -- 7.5 Prevention Strategies for Acute Mountain Sickness (AMS) and High-Altitude Cerebral Edema (HACE) -- 7.5.1 Non-Pharmacological Strategies -- 7.5.2 Other Strategies -- 7.5.3 Pharmacological Strategies -- 7.6 Treatment of HAI -- 7.6.1 Treatment of Acute Mountain Sickness -- 7.6.2 Treatment of High-Altitude Cerebral Edema -- 7.6.3 Treatment of High-Altitude Pulmonary Edema -- 7.7 Better Prophylactics and Therapeutics -- References -- 8: Proteomics as a Potential Tool for Biomarker Discovery -- 8.1 Introduction -- 8.2 How Proteomics Is Useful? -- 8.2.1 History of Proteomics -- 8.2.2 Overview of Proteomics -- 8.2.3 Types of Proteomics -- 8.2.3.1 Protein Expression Proteomics -- 8.2.3.2 Structural Proteomics -- 8.2.3.3 Functional Proteomics -- 8.2.3.4 Clinical Proteomics -- 8.2.4 Proteomics as a Platform to Discover Potent Biomarker -- 8.3 Common Proteomic Approaches -- 8.3.1 Two-Dimensional Gel Electrophoresis (2DGE) -- 8.3.2 Two-Dimensional Difference Gel Electrophoresis (2D-DIGE) -- 8.3.3 Mass Spectrometry (MS) -- 8.3.3.1 MALDI-TOF MS -- 8.3.3.2 ESI MS/MS -- 8.3.3.3 Surface-Enhanced Laser Desorption Ionization (SELDI) -- 8.3.3.4 ``Short-Gun´´ Approach -- 8.3.4 Isotope-Coded Affinity Tag (ICAT) -- 8.3.5 Isobaric Tag for Relative and Absolute Quantitation (iTRAQ) -- 8.4 Biomarker and Disease -- 8.4.1 Autoimmune Disease. 8.4.1.1 Rheumatoid Arthritis (RA) -- 8.4.1.2 Systemic Lupus Erythematosus (SLE) -- 8.4.1.3 Type 1 Diabetes (Diabetes Mellitus) -- 8.4.1.4 Multiple Sclerosis -- 8.5 Conclusion -- References -- 9: Serum and Plasma Proteomics for High Altitude Related Biomarker Discovery -- 9.1 Introduction -- 9.2 Plasma and Serum and Their Potentials in the Diagnosis -- 9.3 Proteomics Approaches to Study Plasma and Serum -- 9.3.1 Immunoblotting -- 9.3.2 2D Gel Electrophoresis and Mass Spectrometry -- 9.3.3 Non-gel Based Quantitative Proteomics -- 9.4 Key Considerations for Biomarker Discovery for High Altitude Physiology -- 9.5 Potentials Biomarker Candidates in High Altitude Pathophysiology -- 9.5.1 Antioxidant Signaling -- 9.5.2 Lipid Metabolism -- 9.5.3 Cytoskeleton Remodeling -- 9.5.4 Post-Translational Modifications -- 9.6 Future Prospects and Conclusion -- References -- 10: Saliva Proteomics as Non-Invasive Application for Biomarker Studies -- 10.1 Saliva: A Novel Informative Sample -- 10.2 Hypobaric Hypoxia: A Pathophysiological Condition -- 10.3 Redox Stress: Molecular Responses in Hypobaric Hypoxia -- 10.4 Use of Biological Fluids Such as Plasma/Serum in Search of Potential Protein Markers -- 10.5 Saliva as a Diagnostic Fluid in Translational Studies -- 10.6 Saliva in Response to Hypobaric Hypoxia -- 10.7 Proteins Evolved as Biomarkers for Hypobaric Hypoxia -- 10.7.1 Alpha-Enolase -- 10.7.2 Cystatins -- 10.7.3 Apoptosis Inducing Factor 2 (AIF2) -- 10.7.4 Prolactin Inducible Protein (PIP) -- 10.7.5 Carbonic Anhydrase 6 (CA6) -- 10.7.6 Phospholipid Transfer Protein (PLTP) -- 10.7.7 Interleukin 1 Receptor Antagonist (IL1R1) -- 10.7.8 Albumin, Alpha-1 Acid Glycoprotein, and Alpha-1 Antitrypsin -- 10.8 Concluding Remarks -- References -- 11: Role of Genomics, Proteomics, and Antioxidant Interventions in Preventing High Altitude Sickness -- 11.1 Introduction. 11.1.1 Role of Genetic Factors Towards High Altitude Sickness -- 11.1.2 Role of Proteomics Towards High Altitude Sickness -- 11.1.3 Role of Antioxidants Towards High Altitude Sickness -- 11.2 Conclusion -- References -- 12: High Altitude Sickness and Antioxidant Interventions -- 12.1 Introduction -- 12.2 Acute Mountain Sickness (AMS), High Altitude Cerebral Edema (HACE), and High Altitude Pulmonary Edema (HAPE) -- 12.3 Diverse Strategies for Preventing High Altitude Sickness (HAS) -- 12.3.1 Pharmacological Interventions -- 12.3.2 Non-Pharmacological and Miscellaneous Interventions -- 12.4 Cellular Antioxidant System and its Alteration in Relation to HAS -- 12.5 Role of Antioxidant Interventions and Prophylactic Benefits in HAS -- References -- 13: Antioxidant Therapy for High Altitude Sickness and Nano-Medicine -- 13.1 Introduction -- 13.2 From Physiological to Molecular: Change of Perspectives -- 13.3 Stabilization of HIF in Signaling of ROS During Hypoxic Conditions -- 13.4 Association of PGC-1 α and Sirtuins with HIF-1α in Signaling of ROS -- 13.5 Nuclear Erythroid-Related Factor 2 -- 13.6 Oxidative Stress Markers at High Altitude -- 13.7 Physiological Consequences of Oxide Generated Stress -- 13.8 Antioxidant Therapy for High Altitude Sickness -- 13.9 Effects on Antioxidant System at High Altitude -- 13.10 Status of Antioxidant Defense System in Body -- 13.11 Antioxidant Therapy: Prevention of High Altitude Sickness -- 13.12 Nano-Medicine in Acute Mountain Sickness -- 13.12.1 Beginning of Nanotechnology -- 13.12.2 Nano-Formulations -- 13.12.3 Hypoxic Nano-Formulations -- 13.12.4 Hypobaric Hypoxia and Nano-Formulations -- 13.12.5 Nano-Curcumin for Hypobaric Hypoxia -- 13.12.6 Nanoceria for Hypobaric Hypoxia -- 13.12.7 Nano-Formulations Forthcoming for Hypobaric Hypoxia -- 13.13 Conclusion -- References. |
| Record Nr. | UNINA-9910741154303321 |
| Singapore : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Histoplasma and Histoplasmosis / / edited by Felix Bongomin
| Histoplasma and Histoplasmosis / / edited by Felix Bongomin |
| Pubbl/distr/stampa | London : , : IntechOpen, , 2020 |
| Descrizione fisica | 1 online resource (92 pages) |
| Disciplina | 616.2 |
| Soggetto topico | Histoplasmosis |
| ISBN | 1-83962-962-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910417991303321 |
| London : , : IntechOpen, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Histoplasma and Histoplasmosis / / Felix Bongomin, editor
| Histoplasma and Histoplasmosis / / Felix Bongomin, editor |
| Pubbl/distr/stampa | London : , : IntechOpen, , 2020 |
| Descrizione fisica | 1 online resource (92 pages) |
| Disciplina | 616.2 |
| Soggetto topico | Histoplasmosis |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910688476603321 |
| London : , : IntechOpen, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Histoplasmosis / / Stephen Berger
| Histoplasmosis / / Stephen Berger |
| Autore | Berger Stephen |
| Pubbl/distr/stampa | Los Angeles : , : Gideon Informatics, Incorporated, , 2021 |
| Descrizione fisica | 1 online resource (85 pages) |
| Disciplina | 616.2 |
| Soggetto topico | Histoplasmosis |
| ISBN | 1-4988-3283-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Histoplasmosis |
| Record Nr. | UNINA-9910794570003321 |
|
Berger Stephen
|
||
| Los Angeles : , : Gideon Informatics, Incorporated, , 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Histoplasmosis / / Stephen Berger
| Histoplasmosis / / Stephen Berger |
| Autore | Berger Stephen |
| Pubbl/distr/stampa | Los Angeles : , : Gideon Informatics, Incorporated, , 2021 |
| Descrizione fisica | 1 online resource (85 pages) |
| Disciplina | 616.2 |
| Soggetto topico | Histoplasmosis |
| ISBN | 1-4988-3283-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Histoplasmosis |
| Record Nr. | UNINA-9910809544803321 |
|
Berger Stephen
|
||
| Los Angeles : , : Gideon Informatics, Incorporated, , 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Histoplasmosis : global status / / Stephen Berger
| Histoplasmosis : global status / / Stephen Berger |
| Autore | Berger Stephen |
| Pubbl/distr/stampa | Los Angeles, California : , : Gideon, , 2017 |
| Descrizione fisica | 1 online resource (59 pages) : color illustrations |
| Disciplina | 616.2 |
| Soggetto topico | Histoplasmosis |
| ISBN | 1-4988-1595-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910164208803321 |
|
Berger Stephen
|
||
| Los Angeles, California : , : Gideon, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
